Published in Anticancer Drugs on June 01, 2002
A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer (2004) 1.17
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. Invest New Drugs (2006) 1.00
Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One (2013) 0.93
FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin. J Cell Mol Med (2014) 0.89
Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel. J Transl Med (2013) 0.87
Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol (2016) 0.75
[Evaluating the benefits of mammographic breast cancer screening]. Orv Hetil (2010) 2.02
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol (2006) 1.85
Oxaliplatin-related side effects: characteristics and management. Semin Oncol (2002) 1.59
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist (2010) 1.52
2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatr Blood Cancer (2009) 1.39
Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys (2008) 1.34
18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm (2009) 1.22
The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med (2011) 1.13
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs (2011) 1.07
Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol (2002) 1.06
Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging (2009) 1.00
Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol (2002) 0.87
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin Cancer Res (2004) 0.86
[Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer]. Bull Cancer (2007) 0.84
Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep (2005) 0.82
COX-2 inhibitors in oncology. Semin Oncol (2003) 0.80
Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients. Breast J (2007) 0.79
Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials. Clin Cancer Res (2004) 0.78
Follicular dendritic cell tumor of the mediastinum: expression of fractalkine and SDF-1alpha as mast cell chemoattractants. Virchows Arch (2006) 0.78
Future directions in the treatment of pancreatic cancer. Semin Oncol (2002) 0.78
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist (2002) 0.78
[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)]. Bull Cancer (2004) 0.77
Prospective, double-blind, randomized trial of equimolar mixture of nitrous oxide/oxygen to prevent pain induced by insertion of venous access ports in cancer patients. Support Care Cancer (2005) 0.76
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Invest New Drugs (2006) 0.76
[Interests and perspectives of PET-CT for breast cancer: review of the literature]. Bull Cancer (2007) 0.75
Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). Crit Rev Oncol Hematol (2007) 0.75
[Node negative breast cancer. Beyond international consensus: a pragmatic approach]. Bull Cancer (2011) 0.75
[History of medical oncology]. Bull Cancer (2013) 0.75
[Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin bêta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]. Bull Cancer (2008) 0.75
[Standards & options: recommendations for the use of erythropoiesis-stimulating agents (ESA) in anaemic cancer patients undergoing radiotherapy (2007 update)]. Cancer Radiother (2008) 0.75
Decision making process in oncology practice: is the information available and what should it consist of? Crit Rev Oncol Hematol (2005) 0.75
[Lung cancers in the elderly]. Bull Cancer (2008) 0.75
[Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year]. Bull Cancer (2002) 0.75
[Decision making process in oncology: rationale and delineation of a composite index of relative antitumoral efficacy (In-RATE)]. Bull Cancer (2008) 0.75
[Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors]. Therapie (2009) 0.75
[Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy]. Bull Cancer (2005) 0.75